Skip to content

Stefanie Cavalcanti

4 papers in the library · 42 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.

The Journal of Clinical Psychiatry January 21, 2026 Matheus G Marques, Aysegul Özerdem, Simon Kung et al. 1 citation

Objective: Treatment-resistant depression (TRD) affects one-third of patients with major depressive disorder, leading to increased morbidity, health care costs, and suicide risk. TRD lacks a standardized definition, complicating treatment selection. Current guidelines often group treatments broadly without clear prioritization, and evidence gaps persist, particularly regarding newer...

Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.

Journal of Affective Disorders August 15, 2025 Stefanie Cavalcanti, Vanessa K Pazdernik, Jennifer L. Vande Voort et al. 3 citations

Chronic stress is a risk factor for depression and may contribute to treatment resistance. This historical cohort study examined the association between baseline perceived stress, measured with the Perceived Stress Scale (PSS), and response to (es) ketamine in treatment-resistant depression (TRD). Adult TRD patients who received intravenous racemic ketamine or intranasal esketamine were...

The Use of Ketamine for the Treatment of Anhedonia in Depression.

CNS Drugs August 1, 2024 Liliana Patarroyo-Rodriguez, Stefanie Cavalcanti, Jennifer L. Vande Voort et al. 13 citations

Anhedonia, a complex symptom rooted in deficits across reward processes, is primarily linked to depression and schizophrenia but transcends diagnostic boundaries across various mental disorders. Its presence correlates with poorer clinical outcomes, including an increased risk of suicide and diminished response to treatment. The neurobiological underpinnings of anhedonia remain incompletely...

Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis

Journal of Affective Disorders March 1, 2023 Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira et al. 25 citations

Background: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). Methods: We searched MEDLINE, Web of Science, Embase,...